Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant
HIV can be transmitted from an HIV infected mother to her infant through her breast milk. The purpose of this study is to determine whether giving infants of HIV infected mothers the anti-HIV drug nevirapine (NVP) for six weeks will reduce the risk of HIV transmission.
Study hypothesis: Six weeks of nevirapine prophylaxis provided to the infant will decrease HIV transmission through breastfeeding.
Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding
The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months
A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies